Published in Circulation on December 18, 2001
Biological activities of C1 inhibitor. Mol Immunol (2008) 1.46
Complement in ischemia reperfusion injury. Am J Pathol (2003) 1.15
The complement system in ischemia-reperfusion injuries. Immunobiology (2012) 1.10
Effect of a lung recruitment maneuver by high-frequency oscillatory ventilation in experimental acute lung injury on organ blood flow in pigs. Crit Care (2006) 1.01
C1 inhibitor: biologic activities that are independent of protease inhibition. Immunobiology (2006) 0.98
C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol (2005) 0.96
The Emerging Role of TLR and Innate Immunity in Cardiovascular Disease. Cardiol Res Pract (2012) 0.95
Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model. Clin Exp Immunol (2006) 0.89
The effect of C1 inhibitor on myocardial ischemia and reperfusion injury. Cardiovasc Pathol (2012) 0.85
Complement activity and pharmacological inhibition in cardiovascular disease. Can J Cardiol (2006) 0.83
Bench-to-bedside review: the role of C1-esterase inhibitor in sepsis and other critical illnesses. Crit Care (2011) 0.82
Mannan-binding lectin in cardiovascular disease. Biomed Res Int (2014) 0.81
Cinryze as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety. J Blood Med (2010) 0.78
Complement activation and cardiac surgery: a novel target for improving outcomes. Anesth Analg (2012) 0.78
Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy (2015) 0.77
Safety of C1-inhibitor for clinical use. Circulation (2002) 0.76
Nebulized C1-Esterase Inhibitor does not Reduce Pulmonary Complement Activation in Rats with Severe Streptococcus Pneumoniae Pneumonia. Cell Biochem Biophys (2016) 0.75
Inhibition of complement improves graft outcome in a pig model of kidney autotransplantation. J Transl Med (2016) 0.75
Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A (2001) 17.36
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell (1994) 7.39
The C3-activator system: an alternate pathway of complement activation. J Exp Med (1971) 7.07
C3 proactivator convertase and its mode of action. J Exp Med (1972) 6.94
The plasmid cloning vector pBR325 contains a 482 base-pair-long inverted duplication. Gene (1981) 4.58
Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health (1999) 4.40
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (1999) 4.36
Classification and phylogeny of hydrogenases. FEMS Microbiol Rev (2001) 4.23
On the mechanism of membrane damage by Staphylococcus aureus alpha-toxin. J Cell Biol (1981) 4.06
Escherichia coli hemolysin may damage target cell membranes by generating transmembrane pores. Infect Immun (1986) 3.94
A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies? J Public Health Med (1997) 3.70
Mechanism of membrane damage by streptolysin-O. Infect Immun (1985) 3.26
Lysis of erythrocytes by complement in the absence of antibody. J Exp Med (1970) 3.19
Enzyme-linked immunoassay for detection of PCR-amplified DNA of legionellae in bronchoalveolar fluid. J Clin Microbiol (1995) 3.04
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res (2000) 2.96
Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med (1972) 2.91
The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem (1998) 2.88
Rhinoviruses infect the lower airways. J Infect Dis (2000) 2.83
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
The role of properdin in the alternate pathway of complement activation. J Exp Med (1974) 2.77
Effect of medical and surgical therapy on aortic dissection evaluated by transesophageal echocardiography. Implications for prognosis and therapy. The European Cooperative Study Group on Echocardiography. Circulation (1993) 2.74
Targeted disruption of the Nijmegen breakage syndrome gene NBS1 leads to early embryonic lethality in mice. Curr Biol (2001) 2.72
Delivery of proteins into living cells by reversible membrane permeabilization with streptolysin-O. Proc Natl Acad Sci U S A (2001) 2.67
Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med (1976) 2.66
Production of listeriolysin by beta-hemolytic strains of Listeria monocytogenes. Infect Immun (1986) 2.66
Gonorrhoea situation in South Greenland in the summer of 1964. Br J Vener Dis (1966) 2.59
Isolation and identification of two hemolytic forms of streptolysin-O. Infect Immun (1984) 2.57
Novel path to apoptosis: small transmembrane pores created by staphylococcal alpha-toxin in T lymphocytes evoke internucleosomal DNA degradation. Infect Immun (1994) 2.47
Activities and cellular localization of yeast proteases and their inhibitors. Biochem Biophys Res Commun (1974) 2.44
Consensus meeting: monosodium glutamate - an update. Eur J Clin Nutr (2006) 2.44
Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff. J Gen Intern Med (1990) 2.44
Diazepam in labour: its metabolism and effect on the clinical condition and thermogenesis of the newborn. Br Med J (1973) 2.42
Locating human quantitative trait loci: guidelines for the selection of sibling pairs for genotyping. Behav Genet (1994) 2.41
The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev (1997) 2.38
Staphylococcal alpha-toxin: oligomerization of hydrophilic monomers to form amphiphilic hexamers induced through contact with deoxycholate detergent micelles. Proc Natl Acad Sci U S A (1981) 2.38
Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation (2001) 2.37
Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol (1999) 2.37
Damage to mammalian cells by proteins that form transmembrane pores. Rev Physiol Biochem Pharmacol (1987) 2.36
Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry (2000) 2.25
Damage to cell membranes by pore-forming bacterial cytolysins. Prog Allergy (1988) 2.23
MRI-Based Topographic Parcellation of Human Neocortex: An Anatomically Specified Method with Estimate of Reliability. J Cogn Neurosci (1996) 2.22
A universal framework for 13C metabolic flux analysis. Metab Eng (2001) 2.18
Recombination of constant and variable modules alters DNA sequence recognition by type IC restriction-modification enzymes. EMBO J (1992) 2.17
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J (1997) 2.16
Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol (1998) 2.16
Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat Genet (1995) 2.16
Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. J Exp Med (1976) 2.13
Molecular nature of the complement lesion. Proc Natl Acad Sci U S A (1978) 2.09
A molecular concept of the properdin pathway. Proc Natl Acad Sci U S A (1976) 2.09
NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. Am J Med Genet (1998) 2.09
Staphylococcal alpha-toxin kills human keratinocytes by permeabilizing the plasma membrane for monovalent ions. Infect Immun (1993) 2.09
Gyri of the human neocortex: an MRI-based analysis of volume and variance. Cereb Cortex (1998) 2.08
Potassium-inhibited processing of IL-1 beta in human monocytes. EMBO J (1995) 2.08
Comparison of intravascular ultrasound and angiography in the assessment of myocardial bridging. Circulation (1994) 2.06
Recommendations on stent manufacture, implantation and utilization. Study Group of the Working Group on Coronary Circulation. Eur Heart J (1997) 2.05
Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation (2001) 2.02
Correlation between toxin binding and hemolytic activity in membrane damage by staphylococcal alpha-toxin. Infect Immun (1984) 2.01
[Conservative therapy of coronary heart disease. Conservative measures]. Internist (Berl) (1997) 2.01
Membrane damage by complement. Biochim Biophys Acta (1983) 2.00
Fatal late vitamin K-deficiency bleeding after oral vitamin K prophylaxis secondary to unrecognized bile duct paucity. J Pediatr Gastroenterol Nutr (1999) 1.98
Complement lysis: the ultrastructure and orientation of the C5b-9 complex on target sheep erythrocyte membranes. Scand J Immunol (1978) 1.95
Chromosome 1 loci in Finnish schizophrenia families. Hum Mol Genet (2001) 1.95
Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. J Clin Microbiol (1995) 1.94
Improved diagnostic value of echocardiography in patients with infective endocarditis by transoesophageal approach. A prospective study. Eur Heart J (1988) 1.90
Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res (1997) 1.89
Circular and linear plasmids of Lyme disease spirochetes have extensive homology: characterization of a repeated DNA element. J Bacteriol (1996) 1.87
Summary of FDA antibody-mediated rejection workshop. Am J Transplant (2011) 1.87
The alternative pathway of complement activation. Adv Immunol (1976) 1.87
Physician orders for life-sustaining treatment (POLST): outcomes in a PACE program. Program of All-Inclusive Care for the Elderly. J Am Geriatr Soc (2000) 1.87
Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry (1973) 1.86
Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol (1986) 1.83
Isolation and characterization of a pigmentless-conidium mutant of Aspergillus fumigatus with altered conidial surface and reduced virulence. Infect Immun (1997) 1.82
Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol (1989) 1.81
Integrating nature and nurture: implications of person-environment correlations and interactions for developmental psychopathology. Dev Psychopathol (1997) 1.79
Biosynthesis of the first component of complement by human and guinea pig peritoneal macrophages: evidence for an independent production of the C1 subunits. J Immunol (1978) 1.79
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
Plasmid analysis and restriction fragment length polymorphisms of chromosomal DNA allow a distinction between Borrelia burgdorferi strains. Zentralbl Bakteriol (1990) 1.77
Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood (1995) 1.75
Activation of Gal4p by galactose-dependent interaction of galactokinase and Gal80p. Science (1996) 1.74
Genome scan of European-American schizophrenia pedigrees: results of the NIMH Genetics Initiative and Millennium Consortium. Am J Med Genet (1998) 1.72
Subcytocidal attack by staphylococcal alpha-toxin activates NF-kappaB and induces interleukin-8 production. Infect Immun (2001) 1.71
Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med (2001) 1.71
The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol Cell Biol (1997) 1.70
Cost of cardiovascular diseases in the United Kingdom. Heart (2006) 1.70
Interaction of the first (C1), the second (C2) and the fourth (C4) component of complement with different preparations of bacterial lipopolysaccharides and with lipid A. J Immunol (1974) 1.69
[Transportation of sick newborn infants]. Ugeskr Laeger (1993) 1.69
Summary of the US FDA approval of belatacept. Am J Transplant (2012) 1.68
The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways. Scand J Immunol (1976) 1.67
Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia (2011) 1.67
Identification and characterization of the dystrophin anchoring site on beta-dystroglycan. J Biol Chem (1995) 1.67
Detection of circulating immune complexes in patients with glomerulonephritis. Kidney Int (1977) 1.66
The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication. J Neural Transm (Vienna) (1997) 1.65
Pathophysiology of impaired right and left ventricular function in chronic embolic pulmonary hypertension: changes after pulmonary thromboendarterectomy. Chest (2000) 1.65
Reduced mortality and brain damage after locomotor activity in gerbil forebrain ischemia. Stroke (1994) 1.65
Protein sorting in Plasmodium falciparum-infected red blood cells permeabilized with the pore-forming protein streptolysin O. Biochem J (1996) 1.64
Cellular and molecular mechanisms for reduced interleukin 4 and interferon-gamma production by neonatal T cells. J Clin Invest (1991) 1.64
A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement. J Exp Med (1974) 1.63